BICOR-BWH Radiopharmaceutical Production & Cyclotron Core

Overview

The Brigham & Women's Hospital BICOR program is a FDA-registered PET drug manufacturer ideally positioned to synthesize novel or literature positron-emitting compounds for human-use studies consistent with federal current Good Drug Manufacturing (cGMP) regulations. Since 2008, our core has provided the research community throughout Mass General Brigham and the Longwood Medical Area with qualified and trained personnel, proven equipment & methods, an ISO-certified sterile radiopharmaceutical processing environment, and robust validation services to safely produce positron-emitting radiotracers for use in research studies.  BICOR enjoys a close partnership with both our institution's Massachusetts-licensed nuclear pharmacy and the PETcore program at Massachusetts General Hospital to provide patient- and study- specific dosage forms to investigators, utilizing the radiopharmaceutical batches manufactured at either Mass General Brigham radiopharmaceutical production core.

Services

  • cGMP-compliant synthesis of radiotracers and radiopharmaceuticals for human use
  • Validation and preparation of regulatory submissions required to support human-use trials
  • Consultation with a multidisciplinary staff with radiopharmaceutical production expertise
  • Autoradiography and pre-clinical investigation of synthetic pathways
  • Small animal PET imaging

 

Currently approved projects may request radiotracers by completing this form and sending to bwhbicor_orders@mgb.org

FY2026 Fee Schedule, effective 10/1/2025

 

Compounds with FDA approved clinical applications

Compounds currently available for research use in humans

Compounds currently available for pre-clinical or calibration use

  • 11C-Acetate (High concentration for prolonged preclinical protocols)
  • 18F-GE179 (GE Healthcare proprietary compound)
  • 18F-GE180 (GE Healthcare proprietary compound)
  • 18F-Fluoride (Available as radiochemical grade only)

Compounds currently under development or consideration

  • 11C-PDMP (novel radiolabel)
  • 18F-VHH (novel radiolabel)
  • 18F-Flurodopa
  • 18F-MMPi
  • 18F-3F4AP
  • 18F-mFBG
  • 18F-Aldoview
  • 18F-CSB321

Compounds with previous development & manufacturing history at BICOR

* A Mass General Brigham investigator using a Mass General Brigham fund is considered an internal user and will be subject to the institutional overhead rate applied by Mass General Brigham Research Management. The external user fee comprises a direct fee negotiated with the PET Core plus an overhead component. The overhead rate set by Mass General Brigham is 44% for external academic users and 59% for external industry users.  Please note: due to the nature of our PET drug manufacturing services, the Core cannot cover costs associated with uncompleted studies due to equipment failure or circumstances outside of our control.

To receive a quote for a new service you would like performed at either BWH-BICOR or our sister site, the MGH PETcore, please complete this form: https://forms.cloud.microsoft/r/nePJrcVxD6

Please send inquiries to:
MGHPETCore@massgeneralbrigham.org